High-Throughput assessment of ChIP-grade capability with Luminex xMAP technology

Speakers
  • Chief Scientific Officer, EpiCypher
    Biography
      Michael earned his PhD in Molecular Immunology from Imperial College London and completed postdoctoral studies in the Thrombosis Research Institute (London) and with Dr. Steve Buratowski at Harvard Medical School. Prior to joining EpiCypher he was a Principal Investigator in the Department of Cell Biology at Albert Einstein College of Medicine. His work has focused on many key oncology research areas including cell-cycle regulation, DNA repair, epigenetics, gene expression and genetic networks.

    Abstract:

    Histone post-translational modifications (PTMs) play pivotal roles in chromatin dynamics and function, with alterations in the healthy profile associated with diverse human pathologies. The regulation and genomic distribution of PTMs is frequently studied by antibodies, despite the wide suspicion that a significant proportion of these reagents have specificity issues. To address this issue we have developed a high -sensitivity and -throughput approach that leverages the multiplexing ability of xMAP technology. We have created a library of >100 biotinylated PTM-containing designer nucleosomes (dNucs) that can be easily combined with Avidin-coated MagPlex beads and determined the binding profiles of >400 commercial ‘PTM-specific’ antibodies. Our results identify truly capable reagents to a large number of PTM targets, but also provide direct evidence that many antibodies in widespread use are highly cross-reactive. As such the current gold-standard screening approaches (immobilized histone PTM-peptide arrays) have proven poorly predictive of alternate assay platforms. In contrast Luminex assays with PTM-nucleosome substrates can be used to identify antibodies with true Chromatin Immuno- Precipitation (ChIP)-grade potential: this will be integral in creating new reagents to study these disease-relevant targets.


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    SEP 27, 2019 9:00 AM PDT
    C.E. CREDITS
    SEP 27, 2019 9:00 AM PDT
    DATE: September 27, 2019TIME: 9:00am PT, 12:00pm ET Thienopyrazole derivatives have recently emerged as effective antitumoral agents with kinase inhibitory activity. In this s...
    DEC 05, 2019 5:00 AM PST
    C.E. CREDITS
    DEC 05, 2019 5:00 AM PST
    DATE: December 5, 2019TIME: 5:00am PST, 8:00am EST The diagnosis of an active infection by the hepatitis B virus (HBV) relies on testing for the HBV surface antigen (HBsAg). Ov...
    Loading Comments...
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds